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Abstract 
We report a case of primary mucosa-associat-
ed lymphoid tissue (MALT) lymphoma of the
prostate. A 67-year-old man presented with uri-
nary obstruction and an elevated prostate-spe-
cific antigen (PSA) level. A physical examina-
tion revealed mild prostate enlargement and no
lymphadenopathy. A needle biopsy and immu-
nohistochemical studies of the prostate were
performed, which revealed marginal zone B-cell
MALT-type lymphoma. A bone marrow aspira-
tion and biopsy did not show involvement by
lymphoma. Magnetic resonance imaging (MRI)
of the abdomen and the pelvis revealed no lym-
phadenopathy or ascites. There was no involve-
ment of other sites by lymphoma. The patient
was diagnosed and staged as extranodal mar-
ginal zone B-cell MALT-type lymphoma of the
prostate,  low  grade  and  stage  I.  The  patient
received external beam radiation therapy to the
prostate with a total dose of 3600cGy in 22 frac-
tions, and became free of disease within the fol-
lowing 15 months.
Introduction
Low-grade  B-cell  mucosa-associated  lym-
phoid tissue (MALT) lymphoma rarely presents
as a primary tumor in extranodal sites other
than in the stomach, which is the most common
site.
1To date only seven cases of primary prosta-
tic MALT lymphoma have been reported in the
literature to our knowledge.
2-8 We report here a
new case that had an elevated prostate-specific
antigen (PSA) level and was treated successful-
ly by external beam radiation therapy alone.  
Case Report
A  67-year-old  man  presented  with  urinary
obstruction. A physical examination revealed
mild  prostate  enlargement  and  no  lymph-
adenopathy  or  hepatosplenomegaly.  Trans-
rectal  ultrasonography  showed  a  4.3x3.2  cm
prostate with high echoic spots in the transi-
tion zone. The laboratory data showed that the
serum PSA level was 7.53 ng/mL (normal: <4.0
ng/mL).  A  transrectal  ultrasound-guided
prostate needle biopsy was performed and the
prostatic tissues of the biopsy demonstrated
diffuse  lymphoid  infiltrations  extending  in
most areas in 12 of 12 biopsy specimens. The
lymphoid cells invaded the prostate glandular
epithelium  and  the  characteristic  lympho-
epithelial lesions were seen (Figure 1). 
The lymphoid cells in these areas were uni-
form in size and shape. They were each char-
acterized by a scanty, clear cytoplasm and a
round, slightly cleaved nucleus. The morpho-
logic  features  were  those  of  centrocyte-like
cells (Figure 2). 
In addition, cells with plasma cell differenti-
ation  were  seen.  The  immunohistochemical
analysis showed that the lymphoid cells were
positive  for  CD79a  and  partially  positive  for
CD20, and that a small number of cells were
positive  for  CD3.  These  histological  results
confirmed a low-grade MALT lymphoma of the
prostate. A bone marrow aspiration and biopsy
did  not  show  involvement  by  lymphoma.
Magnetic  resonance  imaging  (MRI)  of  the
abdomen  and  pelvis  revealed  no  lym-
phadenopathy  or  ascites.  Positron  emission
tomography  (PET)  images  showed  abnormal
uptake  only  in  the  prostate.  There  was  no
involvement of other sites by lymphoma. The
patient was diagnosed and staged as a margin-
al zone B-cell MALT-type of non-Hodgkin’s lym-
phoma of the prostate, low grade and stage I. 
The patient received external beam radia-
tion therapy to the prostate with a total dose of
3600cGy in 22 fractions. A follow-up biopsy of
the prostate was performed 12 months after
the radiation therapy. The immunohistochemi-
cal analysis showed that a small number of lym-
phocytes were more dominantly positive for CD3
than CD20 and CD79a, and negative for CD10,
Bcl2, and CD20. Light chain restriction staining
also showed no κ- and λ-reactivity. These find-
ings  confirmed  no  recurrence  of  MALT  lym-
phoma of the prostate. The patient was free of
disease within the following 15 months.
Discussion
The criteria for primary prostatic lymphoma
includes disease limited to the prostate and
adjacent soft tissue, absence of lymph node
involvement,  and  a  systemic  lymphoma-free
interval of at least one month.
9Primary prosta-
tic lymphoma is rare. It accounts for 0.1% of
newly  diagnosed  lymphomas  and  comprises
less  than  0.09%  of  all  prostate  neoplasms.
10
Primary prostatic MALT lymphoma is extreme-
ly rare and its clinicopathological features are
not well clarified. To our knowledge only seven
cases have been reported previously. Clinical
features of these seven cases, as well as that
of our case, are shown in Table 1. The patients
were elderly men with a mean age of 73 years
(57-87 yr). The most frequent symptom was
urinary tract obstruction. Three patients had
elevated PSA levels (>4.0 ng/mL). The diagno-
sis of prostatic MALT lymphoma was made by
transurethral  resection  (TUR)  in  seven
patients and a trans-rectal needle biopsy in
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Figure  1.  Lymphoid  cells  invading  the
prostate gland-ular epithelium. 
Figure 2. Cells with scanty clear cytoplasm
and a round, slightly cleaved nucleus. [page 170] [Rare Tumors 2009; 1:e55]
one patient. All patients had clinical stage I
disease  except  for  one  case  with  tumor
involvement in the epididymis and spermatic
cord.  Seven  patients  underwent  TUR,  three
had  additional  chemotherapy,  and  one  had
additional radiotherapy. Our patient was treat-
ed by radiotherapy alone according to the non-
Hodgkin’s  lymphoma  (NHL)  medical  guide-
line.  The  clinical  course  in  each  case  was
favorable, although one patient died of other
causes. Another site of marginal zone B-cell
lymphoma of the MALT type was characterized
by  a  high  frequency  of  localized  extranodal
disease  and  a  prolonged  survival,  whereas
nodal marginal zone (monocytoid) B-cell lym-
phoma  more  often  occurred  with  advanced-
stage disease and had a worse survival rate.
1
However,  in  case  2,  a  tumor  relapse  was
detected seven years after the initial TUR. It
seems  that  long-term  follow-ups  and  more
reports are needed to clarify the clinical char-
acteristics and pathogenesis of this disease.
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Case Report
Table 1. Clinical features of eight primary prostatic MALT lymphoma.
Case  Age  Symptom Laboratory  Clinical Treatment Response Outcome Follow-up Reference
(years) findings stage (months)
1 75 Hematuria, pyuria Normal II TUR, Cx CR AW 12 2
2 57 Urinary obstruction Normal I TUR, Cx CR AW 18 3
3 84 Urinary obstruction Elavated PSA I TUR CR DOC 24 4
4 67 Prostatism Normal I TUR, Rx CR AW 36 5
5 87 Urinary obstruction Normal I TUR NR NR NR 6
6 79 Urinary obstruction Normal I TUR CR AW 108* 7
7 70 Disuria Elevated PSA I TUR, Cx CR AW 58
8 67 Urinary obstruction Elevated PSA I Rx CR AW 15 Present case
*Relapse was noted 7 years after the initial treatment; AW, alive and well; CR, complete remission; Cx, chemotherapy; DOC, died of other causes; MALT, mucosa-associated lymphoid tissue; NR, not recorded; PSA,
prostate-specific antigen; Rx, radiotherapy; TUR, transurethral resection.